Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
Can-Fite highlighted encouraging clinical observations from its Phase 2a study of namodenoson in pancreatic cancer, noting that enrollment is complete. Several patients demonstrated prolonged disease control, with one patient remaining on therapy and follow-up for approximately 16 months.
Key figures
- Drug Name
- Namodenoson
- Phase Of Trial
- Phase 2a
- Durable response duration
- 16 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.